Immune checkpoint inhibitors have emerged as a pillar in the management of advanced
malignancies. However, nonspecific immune activation may lead to immune-related adverse …

The development of immune checkpoint inhibitors [monoclonal antibodies targeting
cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD …

Immune checkpoint inhibitors have proven to be efficacious for a broad spectrum of solid
organ malignancies. These monoclonal antibodies lead to cytotoxic T-cell activation and …

Dermatologic complications of anti-PD-1/PD-L1 immune checkpo... : Current Opinion in
Oncology Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies …

Immunomodulatory drugs that leverages host immune mechanisms to destroy tumor cells
have been met with great promise in the treatment of cancer. Immunotherapy, targeting …

Immune checkpoint inhibitors (ICIs) are essential components of the cancer therapeutic
armamentarium. While ICIs have demonstrated remarkable clinical responses, they can be …

Antineoplastic agents that use the immune system have revolutionized cancer treatment.
Specifically, implementation of immune checkpoint inhibitors, monoclonal antibodies that …

Nivolumab is a programmed cell death receptor‐1 (PD‐1) antibody used in the treatment of
metastatic or unresectable melanoma. Cutaneous reactions are the most common adverse …

Immunotherapy targeting the programmed cell death 1 (PD-1) receptor has demonstrated
tremendous promise in the treatment of advanced solid tumors. Dermatologic toxicities …

Importance There exists a paucity of literature that summarizes the effective management of
cutaneous immune-related adverse events (cirAEs) in patients with cancer who are …